Amgen’s ovarian cancer drug, Trebananib fails to pass 3rd survival trial phase

November 5, 2014 9:51 AM

1 0

Amgen, the manufacturers of an ovarian cancer drug, Trebananib, are disappointed in the performance of the drug at its late-state third trial phase. Trebananib is supposed to be used alongside Paclitaxel, a chemotherapy drug in order to cure patients of ovarian tumors and promote overall patient survival, but the drug has failed its manufacturers by performing below expectations during trials.

Trebananib has failed to show that it can significantly improve patients’ survival rates, and its efficacy and safety performance has failed to meet secondary endpoint goals of improving survival as set by Amgen, the manufacturer during the Phase 3 trial study. When administered with chemotherapy, t...

Read more

To category page